Ono Pharmaceutical Co., Ltd. (MUN:ON40)

Market Cap	5.45B +20.9%
Revenue (ttm)	2.81B +5.9%
Net Income	380.55M +39.4%
EPS	0.81 +39.5%
Shares Out	n/a
PE Ratio	14.31
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	4.120
Previous Close	4.260
Day's Range	4.120 - 4.120
52-Week Range	3.100 - 4.620
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 8, 2026

About Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabet...

• Industry: Pharmaceutical Preparations
• Founded: 1717
• Employees: 4,287
• Stock Exchange: Munich Stock Exchange
• Ticker Symbol: ON40

Financial Performance

In fiscal year 2026, Ono Pharmaceutical's revenue was 515.79 billion, an increase of 5.94% compared to the previous year's 486.87 billion. Earnings were 69.77 billion, an increase of 39.40%.

Financial numbers in JPY